Evidence map›Paper›PMID 37699923›Full record

ArticleNPJ Parkinson's disease2023

Defining the causes of sporadic Parkinson's disease in the global Parkinson's genetics program (GP2).

Clodagh Towns, Madeleine Richer, Simona Jasaityte, Eleanor J Stafford, Julie Joubert, Tarek Antar, Alejandro Martinez-Carrasco, Mary B Makarious, Bradford Casey, Dan Vitale and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. medRxiv : the preprint server for health sciences · 2026
    Article
  5. Review
  6. Article
  7. Multi-ancestry analysis ofmedRxiv : the preprint server for health sciences · 2026
    Article
  8. Article
  9. Pathology and genetics in a global cohort of Parkinsonian Disorders.medRxiv : the preprint server for health sciences · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. ThemedRxiv : the preprint server for health sciences · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Clodagh TownsDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.
Madeleine RicherDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.ORCID http://orcid.org/0009-0005-4339-4788
Simona JasaityteDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.ORCID http://orcid.org/0009-0009-6030-2901
Eleanor J StaffordDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.ORCID http://orcid.org/0000-0003-2451-4308
Julie JoubertDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.
Tarek AntarMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Alejandro Martinez-CarrascoDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.ORCID http://orcid.org/0000-0001-6191-1703
Mary B MakariousDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.ORCID http://orcid.org/0000-0002-7978-1051
Bradford CaseyDepartment of Clinical Research, Michael J. Fox Foundation for Parkinson's Research, New York City, NY, USA.ORCID http://orcid.org/0000-0002-2623-5997
Dan VitaleNational Institutes of Health, Bethesda, MD, USA.
Kristin LevineCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Hampton LeonardMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Caroline B PantazisNational Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2768-4903
Laurel A ScrevenCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0009-0007-8630-6754
Dena G HernandezMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Claire E WegelDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Justin SolleDepartment of Clinical Research, Michael J. Fox Foundation for Parkinson's Research, New York City, NY, USA.
Mike A NallsMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Cornelis BlauwendraatNational Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9358-8111
Andrew B SingletonMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5606-700X
Manuela M X TanDepartment of Neurology, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-5835-669X
Hirotaka IwakiMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Huw R MorrisDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK. h.morris@ucl.ac.uk.ORCID http://orcid.org/0000-0002-5473-3774
Global Parkinson’s Genetics Program (GP2)

Funding

Genome wide SNP analysis in Parkinson's diseaseZ01AG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2006 to 2008
$2.6M
Intramural NIH HHS Z01 AG000949
6 · The paper itself

Abstract

The Global Parkinson's Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia.

Identifiers

PMID37699923
PMCPMC10497609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.